Recent figures indicate that cancer survival rates among Americans have reached unprecedented levels, the result of years of scientific progress, timely screening, and improved therapies.
A new report from the American Cancer Society highlights a remarkable shift in cancer outcomes across the United States. According to the annual report released on January 13, approximately seven in ten patients now survive five years or longer following a cancer diagnosis. This figure represents a dramatic increase from the mid-1970s, when only half of diagnosed individuals reached the same milestone. The data analyzed covers diagnoses between 2015 and 2021, and the five-year survival benchmark remains a standard measurement for assessing progress against the disease.
The report also underscores a continued decline in cancer mortality rates through 2023, estimating that nearly 4.8 million deaths have been prevented since 1991. Researchers attribute this decline to reductions in smoking, earlier and more precise detection, and improvements in treatment strategies. Rebecca Siegel, lead author of the report and senior scientific director of surveillance research at the American Cancer Society, emphasized that these outcomes reflect the long-term impact of sustained cancer research efforts. She described the progress as a transformation of many cancers from once-lethal diagnoses into manageable or chronic conditions.
The influence of genetics and the impact of targeted therapies
Advances in understanding the genetic underpinnings of cancer have been a key driver of improved survival rates. Dr. Leonard Kalman, executive deputy director and chief medical officer at Miami Cancer Institute, explains that identifying specific genetic mutations in tumors allows physicians to apply precision medicine techniques. “When a mutation is identified, we can often match it with a targeted therapy that either cures patients or extends remission periods,” Kalman noted. This personalized approach is helping to turn previously fatal cancers into conditions that can be treated effectively over time, improving both longevity and quality of life for many patients.
Targeted treatments are increasingly common for cancers such as breast, colorectal, and lung cancers, where molecular profiling guides therapy decisions. Researchers are also expanding the use of immunotherapy, which harnesses the body’s immune system to fight cancer cells, and combination therapies, which pair traditional chemotherapy or radiation with newer drugs. These strategies, combined with early detection through screening programs, have contributed to the substantial gains in survival documented in the report.
Notable improvements in survival for high-mortality cancers
While the overall increases in survival are significant, progress has been especially striking for cancers that were previously associated with low survival rates. Multiple myeloma, a form of bone marrow cancer, has seen five-year survival jump from 32% to 62%. Liver cancer survival has improved from 7% to 22%, and lung cancer rates have risen from 15% to 28%. These improvements illustrate the impact of both scientific advances and public health initiatives aimed at prevention, early diagnosis, and effective treatment.
Despite these positive developments, experts warn that obstacles still exist. Dr. Sara Myers, a breast cancer surgeon and leader of the BRIDGE program at The Ohio State University Comprehensive Cancer Center, explained that although the findings are promising, major gaps in screening and access to care continue. Myers stated, “Ensuring that patients not only benefit from effective treatment but also preserve a strong quality of life by reducing serious side effects is essential.” She stressed that maintaining fair access to care and supportive resources remains vital to sustaining the ongoing rise in survival rates.
Ongoing hurdles and inequalities
Cancer continues to be a leading cause of death in the United States, and certain forms remain particularly deadly. Lung cancer is projected to account for the most cancer-related deaths in 2026, surpassing the combined fatalities from colorectal and pancreatic cancers. Additionally, the incidence of common cancers, including breast and prostate cancer, continues to rise, underscoring the need for ongoing prevention and early detection efforts.
Socioeconomic, racial, and ethnic disparities continue to influence outcomes, with underserved populations often experiencing delayed diagnoses and limited access to advanced treatments. Funding for cancer research, traditionally supported by the federal government, has faced reductions that threaten the sustainability of ongoing studies and the development of new therapies. Shane Jacobson, CEO of the American Cancer Society, warned that setbacks in research funding and health insurance access could undermine progress and slow future breakthroughs.
Dr. Kalman echoed concerns about funding cuts, noting the decades of investment that have finally begun to yield tangible results in patient survival. “To see this progress now potentially compromised is deeply concerning,” he said. The continued support of research initiatives and equitable healthcare policies remains essential to ensure that recent gains in survival are not reversed.
Continued progress and hope
Despite these challenges, the overall trajectory remains positive. Innovations in genetic research, targeted therapies, immunotherapy, and improved public health measures are expected to drive further improvements in cancer outcomes. Increasing awareness about preventive measures, including smoking cessation, healthy diet, regular screenings, and vaccination against cancer-causing viruses, also contributes to better long-term results.
The report underscores that the fight against cancer is far from over. Maintaining investment in research, expanding access to cutting-edge treatments, and addressing disparities are essential to ensure that progress continues. For patients and families affected by cancer, the trends highlighted in the American Cancer Society report offer hope, demonstrating that survival is increasingly attainable and that cancer can often be managed effectively as a chronic condition.
The new findings reflect decades of dedication by researchers, clinicians, and public health advocates to improve cancer outcomes in the United States. With continued investment, innovation, and equitable healthcare access, survival rates are likely to improve further, offering renewed optimism to patients, families, and healthcare providers nationwide.
